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From the Departament de Ciències Fisiològiques II, Universitat de Barcelona, Institut d’Investigació Biomèdica de Bellvitge
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Osterix, a zinc finger transcription factor, is specifically ex-
pressed in osteoblasts and osteocytes of all developing bones.
Because no bone formation occurs in Osx-null mice, Osterix is
thought tobe anessential regulator of osteoblast differentiation.
We report that, in several mesenchymal and osteoblastic cell
types, BMP-2 induces an increase in expression of the two iso-
forms of Osterix arising from two alternative promoters. We
identified a consensus Sp1 sequence (GGGCGG) as Osterix
binding regions in the fibromodulin and the bone sialoprotein
promoters in vitro and in vivo. Furthermore, we show that
Osterix is a novel substrate for p38 MAPK in vitro and in vivo
and that Ser-73 and Ser-77 are the regulatory sites phosphory-
lated by p38. Our data also demonstrate that Osterix is able to
increase recruitment of p300 and Brg1 to the promoters of its
target genes fibromodulin andbone sialoprotein in vivo and that
it directly associates with these cofactors through protein-pro-
tein interactions. Phosphorylation of Osterix at Ser-73/77
increased its ability to recruit p300 andSWI/SNF to either fibro-
modulin or bone sialoprotein promoters.We therefore propose
that Osterix binds to Sp1 sequences on target gene promoters
and that its phosphorylation by p38 enhances recruitment of
coactivators to form transcriptionally active complexes.
Bone is a highly dynamic tissue that is constantly remodeled
throughout life. Bone remodeling activity is dependent on a
delicate balance between osteoclast resorption and osteoblast
new bone formation. Deregulation of these two activities
unleashes pathological states such as osteoporosis and osteo-
sclerosis. Both endochondral and intramembranous ossifica-
tion depends on osteoblasts that are derived from pluripotent
mesenchymal stemcells that, in response to various cellular and
environmental signals, commit to the osteoblast phenotype.
Among them, BMPs5 are essential for commitment and differ-
entiation to the osteoblast lineage; they promote osteoblast dif-
ferentiation in vitro and in vivo, bone regeneration, and ectopic
bone formation in vivo (1–3). The BMP signal is transduced
through the binding to its heteromeric cell membrane recep-
tors (4, 5). BMP binding to receptors results in the activation of
the Smad family of transcription factors, which directly regu-
late target gene expression (6).
BMP target genes include a growing number of osteoblast-
determining transcription factors. For instance, in vivo genetic
evidence as well as osteogenic induction of bone marrow mes-
enchymal stem cells in vitro has identified several types of tran-
scription factors such as Id1, homeodomain proteins such as
Dlx3 and Dlx5, ATF4, Runx2, and Osterix (Osx) (7–9). Runx2
and Osx have been widely accepted as master osteogenic fac-
tors because neither Runx2- nor Osx-null mice form mature
osteoblasts (10, 11). Osx contains a proline- and serine-rich
transactivation domain located in the N-terminal part of the
protein and three zinc fingers with homology to the Sp1/Krup-
pel transcription factor family. Osx expression is specifically
restricted to osteoblasts and osteocytes of all developing bones.
In Osx-null mice, no bone formation takes place, although
Runx2 is expressed, suggesting that Osx acts downstream of
Runx2 during bone development (11). Moreover, it has been
suggested that Runx2may function from the commitment step
to the point where osteochondroprogenitors appear, whereas
Osx may have a role in the segregation of osteoblasts from
osteochondroprogenitors (8). In addition, it has been shown
that genetic polymorphisms in the Osx gene locus are associ-
ated with low bone mineral density (12, 13). This essential role
ofOsx relies on its ability to regulate the expression of a number
of osteoblast markers such as osteopontin, osteocalcin, Dkk1,
and collagen type I. In addition, transcriptional regulators such
as NFATc or NO66 have been shown to interact with Osx and
regulate its transcriptional responses (14, 15).
Runx2 andOsx transcription is stimulated byBMP treatment
in vitro (11, 16, 17). Pretreatment with cycloheximide blocks
Osx induction, suggesting that Osx is not a direct target of the
BMP signaling cascade but requires the expression of newly
synthesized intermediates (18). Interestingly, although expres-
sion of Osx in vivo requires Runx2, BMP-2 is still able to stim-
ulate alkaline phosphatase activity and Osx expression in
Runx2-deficient cells (18). Recent data indicate that BMP-2
activates expression of Osx through Runx2-dependent as well
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ològiques II, Universitat de Barcelona, IDIBELL, C/Feixa Llarga s/n., E-08907
L’Hospitalet de Llobregat, Spain. Tel.: 34-934024281; Fax: 34-934024268;
E-mail: fventura@ub.edu.
5 The abbreviations used are: BMP, bone morphogenetic protein; Osx,
Osterix; Fmod, fibromodulin; Ibsp, bone sialoprotein; MEF, mouse
embryonic fibroblast; qPCR, quantitative PCR; HDAC, histone deacety-
lase; ANOVA, analysis of variance.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 285, NO. 42, pp. 31985–31994, October 15, 2010
© 2010 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
OCTOBER 15, 2010 • VOLUME 285 • NUMBER 42 JOURNAL OF BIOLOGICAL CHEMISTRY 31985
This is an Open Access article under the CC BY license.
as -independentmechanisms involvingDlx5 andMsx2 (17, 19).
These studies also showed that BMP-2 induction of Osx
required the transcriptional activation of Dlx5 by p38 MAPK-
mediated phosphorylation (17, 20).
Activation of p38 MAPK signaling by BMP-2, insulin-like
growth factor I, or mechanical stress has been shown to be
relevant in the induction of their osteogenic effects (20–25).
Thus, although these data suggest that osteoblast-specific tran-
scription factors and p38 are involved in BMP-induced Osx
expression, little is known about the transcriptional mecha-
nisms by which Osx promotes osteoblast-specific gene expres-
sion. In this study, we identified a consensus Sp1 sequence
(GGGCGG) as the Osx binding regions in the fibromodulin
(Fmod) and the bone sialoprotein (Ibsp) promoters in vitro
and in vivo. We also show that Osx is a novel substrate for
p38MAPK in vitro and in vivo and that Ser-73 and Ser-77 are
the regulatory sites phosphorylated by p38. The transactiva-
tion potential of Osx was increased by p38 phosphorylation
at least in part through increased interaction of Osx with the
transcriptional cofactors p300 and Brg1. We propose a regula-
tory network in which BMP-2 activates expression of Osx and
enhances its transcriptional activation by p38-mediated
phosphorylation.
EXPERIMENTAL PROCEDURES
Plasmids, Reagents, and Antibodies—cDNA fragments en-
coding both long and short Osterix-pCDNA3 expression vec-
tors were kindly provided by Dr. K. Watanabe and Dr. B. de
Crombrugghe, respectively. Osx cDNA was used as a parental
plasmid to generate the phosphorylation mutants using PCR
approaches or subcloned into pGEX vector to generate bacte-
rial GST-Osx fusion constructs. Activated MKK6 expression
vector (MKK6EE) and recombinant p38were provided byDr. P.
Muñoz-Cánoves. Fmod promoter-reporter construct from
2032 to 100 (2-kb pFmod-Luc) was kindly provided by Dr.
F. Cimino. The pFmod300-Luc promoter-reporter was gener-
ated by PCR. The Ibsp promoter-reporter (pIbsp-Luc) con-
struction encoding a conserved 300-bp enhancer of human
IBSP gene, located at12400 from the transcriptional start site,
was cloned in the minimal promoter of c-fos gene. BMP-2 was
generously provided by Wyeth and was used at a final concen-
tration of 2 nM. SB203580 (Calbiochem) was used at a final
concentration of 10 M. Antibodies against Osx (Abcam),
phosphoserine (Abcam),MKK6 (Abcam), Brg1 (Upstate), p300
(Santa Cruz Biotechnology), and -tubulin (Sigma) were used
at 1:1000.
Cell Culture and Transfection—C2C12, Saos-2, and mouse
embryonic fibroblast (MEF) cell lines were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen).
MC3T3-E1 cell line was maintained in the -modified mini-
mum Eagle’s medium (LabClinics) supplemented with 10%
fetal bovine serum (FBS). Human primary osteoblasts were
obtained from Lonza and cultured in DMEM/F-12 supple-
mented with 15% FBS, 10 g/ml ascorbic acid, and 1.25 g/ml
amphotericin B. Bone marrow mesenchymal stem cells were
maintained in DMEM supplemented with 15% FBS. All media
were supplemented with 0.2 mM glutamine, 0.1 mM pyruvate,
and 100 units/ml penicillin-streptomycin. C2C12, MC3T3-E1,
MEF, and Saos-2 cell differentiation was induced with medium
lacking serum and BMP-2 at a final concentration of 2 nM. For
human primary osteoblasts, differentiation was induced with
medium lacking serum, 50 g/ml ascorbic acid, and 2 nM
BMP-2, and for bone marrow mesenchymal stem cells, differ-
entiation was induced with 10% FBS, 50M ascorbic acid, 5mM
-glycerophosphate, and 2 nMBMP-2. C2C12,MC3T3-E1, and
MEF cells were transiently transfected using Lipofectamine
LTX (Invitrogen).
Western Blot Analysis—Cells were washed twice in cold PBS
and lysed with 50 mM Tris, pH 7.5, 150 mM NaCl, 0.2% Igepal,
10% glycerol supplemented with protease and phosphatase
inhibitors. Protein extracts were resolved on 10% SDS-poly-
acrylamide gels, transferred to nitrocellulose membrane (Mil-
lipore), and subjected toWestern blot using the above indicated
antibodies at 1:1000 dilution. Immunocomplexes were visual-
ized with a horseradish peroxidase-conjugated anti-rabbit or
anti-mouse IgG antibody (1:10,000) followed by incubation
with ECLWestern blot reagent (GE Healthcare).
Immunofluorescence Assay—24 h after either transfection
with Osx or treatment with BMP-2, C2C12 cells were fixed
as described previously (17). Cells were stained with rabbit
anti-Osx (Abcam) at 1:500 followed by goat anti-rabbit IgG
conjugated with Alexa Fluor 488 at 1:400. Labeling was
detected using a Leica TCS SL inverted laser scanning con-
focal microscope.
Quantitative PCR (RT-qPCR) Analysis—Total RNA was iso-
lated from C2C12, MC3T3-E1, Saos-2, and bone marrow mes-
enchymal stem cells using the Ultraspec RNA Isolation System
(Biotecx). 5 g of total RNA were reverse transcribed using a
High Capacity cDNA Reverse Transcription kit (Applied Bio-
systems). Quantitative PCRs were carried out using the ABI
Prism 7900 HT Fast Real Time PCR System and a TaqMan
5-nuclease probe method (Applied Biosystems). All tran-
scripts were normalized toGAPDH, and transfection efficiency
was assessed by GFP expression. Designed human TaqMan as-
says (Applied Biosystems) were used to quantify gene expres-
sion of Osx (Mm00504574_m1), Fmod (Mm00491215_m1),
Ibsp (Mm00492555_m1), and GAPDH (Mm99999915_g1).
Reporter Assays—Luciferase activities were quantified using
the Luciferase Assay System (Promega). Luciferase values were
normalized using -galactosidase activity measured with the
Luminescent -Galactosidase Detection kit II (Clontech).
Biotinylated Oligonucleotide Precipitation Assays—C2C12
cells were lysed as described previously (26). Biotinylated oligo-
nucleotides were incubated overnight with cell extracts in the
presence of 1 g of poly(dI-dC) (GE Healthcare) and collected
with streptavidin-agarose beads (GE Healthcare). Bound Osx
was detected by immunoblotting.
Chromatin Immunoprecipitation—Chromatin immuno-
precipitation assays were performed using the Chromatin
Immunoprecipitation Assay kit (Upstate) according to the
manufacturer’s instructions but repeating all the washes twice.
Antibodies used were anti-Osx (Abcam), anti-p300 (N-15,
Santa Cruz Biotechnology), Brg1 (Upstate), anti-RNA poly-
merase II, and anti-IgG (Upstate). Primer sequences used for
the PCR were as follows: for human primary osteoblasts and
Saos-2 cells, HsIbspF, 5-cttctttctcatgtggccaacactcg; HsIbspR,
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5-tggcatcaggagatgtcctctctt; HsFmodF, 5-ggacccagggctgccaat;
and HsFmodR, 5-cgtccctctgtctggcctccttgggtt; and for C2C12
cells, MmIbspF, 5-ttcaggctgccaatgctccagggaa; MmFmodR, 5-
tgaccacgtccttctgtctggtct; MmIbspF, 5-ccagttttcaaacatccaaatc-
catagg; and MmIbspR, 5-ttggcactgggagatgtcctccctt.
Immunoprecipitation—Cells were lysed as above. The super-
natant fractionwas incubatedwith 1g of anti-FLAG-M2 anti-
body (Sigma) overnight followed by incubation with protein
G-Sepharose beads for 1 h. Bound proteins were washed four
times in lysis buffer. Bound proteins were detected by immu-
noblotting using the antibodies described above.
In Vitro Phosphorylation by p38 MAPK—GST-p38 MAPK
was activated by MBP-MKK6-DD (5:1 ratio) in 50 mM Tris-
HCl, pH 7.5, 10mMMgCl2, 2 mMDTT, 200 MATP. Activated
p38 (200 ng for each condition) was incubated with recombi-
nant Osx proteins in the same buffer supplemented with 1 M
ATP and 3 pmol of [-32P]ATP at 30 °C for 20 min.
RESULTS
Expression of Two Isoforms of Osterix Is Stimulated by BMP-
2 in Mesenchymal and Osteogenic Cells—Previous studies
showed thatOsxmRNA levels increase after BMP-2 addition in
mesenchymal cell types, including primary osteoblasts, mesen-
chymal stem cells, mesenchymal C2C12 cells, and osteoblast
MC3T3-E1 cells (11, 17, 20, 27). Analysis of protein expression
by immunoblotting indicated that Osx was not significantly
expressed in undifferentiated C2C12 cells or MC3T3-E1 cells
and showed some expression in the osteoblastic cell line Saos-2
(Fig. 1A). However, Osx protein levels were strongly increased
in all cell types at 24 h after addition of 2 nM BMP-2. In all cell
types,Osx appeared asmultiple bands of differentmobility (Fig.
1A). Previous work showed that both the human and mouse
Osx mRNAs are expressed as two isoforms arising from two
alternative promoters (28–30). RT-PCR using unique 5-prim-
ers and a common 3-primer yielded different species that cor-
responded to the long (MASSLL) and the short isoforms
(MLTAAC) of Osx. These results indicated that both isoforms
are induced at significant levels by BMP-2 in these cell lines
(Fig. 1B). We also analyzed the subcellular localization of Osx
after BMP-2 induction. Immunofluorescence analysis of
C2C12 cells, either transfected with an Osx expression vector
or 24 h after BMP-2 addition, showed that Osx is a constitu-
tively nuclear transcription factor (Fig. 1C).
Osx-responsive Regions in Promoters of Fibromodulin and
Bone Sialoprotein—To analyze the mechanisms of transcrip-
tional activation by Osx, we usedmicroarrays to search for Osx
target genes by comparing RNA expression of C2C12 cells
transfected with a mock construct or transfected with an Osx
expression vector. Among the differentially expressed genes,
we focused on Fmod, whose expression increased 2-fold in
response to Osx. We also focused on Ibsp as a late osteoblast
marker; its expression has been shown to be abolished in Osx-
deficient cells (11, 31). RT-qPCR confirmed that Osx overex-
pression increased the expression levels of both Fmod and Ibsp
in C2C12.Moreover, we analyzed the expression levels of Fmod
and Ibsp in MC3T3-E1 cells. Similarly to C2C12 cells, Osx
induced expression of both genes (Fig. 2A).
We also analyzed the temporal expression pattern of both
Fmod and Ibsp in response to BMP-2 comparedwith the induc-
tion of Osx. As shown in Fig. 2B, induction of Fmod and Ibsp
FIGURE 1. Expression of two isoforms of Osterix by BMP-2 in mesenchy-
mal and osteogenic cells. A and B, cells were treated with BMP-2 in medium
without serum for 24 h. A, Osx and tubulin were detected by immunoblotting.
B, both short (S) and long (L) Osx mRNA were detected by PCR from cells
treated with 2 nM BMP-2 for 24 h using specific forward primers (short, 5-cac-
ccattgccagtaatcttcaagcca; long, 5-ctcgaggatggcgtcctctctgcttg) and a com-
mon reverse primer (5-ggactgcctgcaggagagagga). C, subcellular localization
of Osx in C2C12 cells was analyzed by immunofluorescence with anti-Osx
antibody in cells either transiently transfected with short Osx construct or
incubated in medium without serum and treated with BMP-2 for 24 h. Scale
bar, 10 m.
FIGURE 2. Fmod and Ibsp expression is induced by Osx. A, cells were tran-
siently transfected with mock or Osx construct overnight and incubated in
medium without serum for 24 h. Fmod and Ibsp mRNAs were measured by
RT-qPCR, normalized to GAPDH, and expressed as relative expression  S.E.
of four independent experiments. Expression of the different constructs was
analyzed by immunoblotting (data not shown). B, confluent cells were incu-
bated in medium without serum overnight and treated with BMP-2 for the
indicated times. Osx, Fmod, and Ibsp mRNAs were measured by RT-qPCR,
normalized to GAPDH, and plotted as relative expression to time 0  S.E. of
three independent experiments (***, p  0.001 compared with mock condi-
tion, two-way ANOVA followed by Bonferroni’s test).
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gene expression in either C2C12 or MC3T3-E1 cells strongly
correlated with that of Osx. All genes required at least 8 h to
increase their mRNA levels significantly after BMP-2 addition.
Because these findings suggested that eitherOsx or BMP-2 is
able to increase Fmod expression, we decided to determine
whether Osx and BMP-2 stimulation was transcriptional by
analysis of Fmod promoter activity. Using a 2-kb upstream reg-
ulatory sequence of the murine Fmod gene (2-kb pFmod-Luc)
in C2C12 cells, we observed a 2.3-fold increase in activation in
cells overexpressing Osx and a 1.7-fold increase in activation
after treatment with 2 nM BMP-2 (Fig. 3A). More interestingly,
BMP-2 promoted an additive effect to Osx overexpression in
C2C12 cells. We then used reporter assays to analyze deletions
of the 2-kb promoter. The deletion of the sequence from2032
to 192 provoked only a slight decreases in Osx or BMP-2
reporter induction (Fig. 3B). Homology analysis using the ECR
Browser showed that the 297/100 region on the Fmod pro-
moter is highly conserved among mammalian species and de-
tected two putative Sp1 transcription factor binding sites
(supplemental Fig. 1 and Ref. 32). Similar analysis on the Ibsp
promoter region detected a highly conserved 300-bp enhancer
located at 12400 bp from the Ibsp transcription start site that
contains a Runx2 binding site, a palindromic homeobox bind-
ing site (TAATTA), and an Sp1 binding site (supplemental Fig. 1).
To test whether this region alone has the ability to render a
minimal promoter responsive toOsx and/or BMP-2, we further
assayed the responses of a reporter construct containing this
region upstream of a heterologous c-fos minimal promoter.
Whereas theminimal c-fos promoter showed no response at all
to Osx or BMP-2, the Ibsp enhancer region was increased 2-
and 3-fold by overexpression of Osx and addition of 2 nM
BMP-2, respectively (Fig. 3C). Similarly to Fmod reporter
assays, BMP-2 promoted an additive effect to Osx overexpres-
sion on this enhancer in C2C12 cells. The reporter assays of
Fmod and Ibsp indicate that, in addition to the induction ofOsx
expression, BMP-2 activates alternative pathways that result in
further Fmod and Ibsp transcriptional activation by Osx.
Osx Interacts with Sp1 Consensus Regions in Regulatory Sites
of Fmod and Ibsp—It has been shown that Osx interacts with
the promoters of osteogenic genes such as Col1a1, Dkk1, or
Bglap in vivo (14, 15, 31). In all cases, a GC-rich canonical Sp1
sequence has been shown to be the specific Osx binding site.
Therefore, we analyzed whether Osx bound to the Sp1
sequence of Fmod (GGGGCGG) and studied the Osx binding
preferences by comparing them with Sp1 sequences located in
the bone enhancer of the Col1a1 promoter (AGGGCGG or
GGGGAGG, respectively) that have been shown to be boundby
Osx (Fig. 4A) (33). We performed oligonucleotide pulldown
assays from either C2C12 cells overexpressingOsx or cells after
induction of endogenousOsx by BMP-2 addition. Osx required
a functional Sp1 site because no binding at all to the DNA was
observed when extracts were incubated with the Sp1-mutated
oligonucleotide (Fig. 4A). The results also suggest that the
sequenceGGGCGG is preferred forOsx binding at least in vitro
because it bound better than the sequence GGGAGG.
To investigate binding of Osterix in both Fmod promoter
and Ibsp enhancer in vivo, we performed chromatin immu-
noprecipitation assays in Saos-2 cells or human primary
osteoblasts treated with 2 nM BMP-2 for 24 h. As shown in
Fig. 4B, binding of Osx to the proximal Fmod promoter or Ibsp
enhancer in vivo was increased after treatment with BMP-2.
The increased binding of Osx to these promoter regions corre-
lated with increased recruitment of RNA polymerase II to the
start site of Fmod gene. It has been reported previously that
p300 histone acetyltransferase is required for the expression of
several osteogenic genes in response to BMP-2 (17, 34–36).
Results of the chromatin immunoprecipitation assay indicated
that p300 was recruited onto both Fmod proximal promoter
and Ibsp enhancer sequences in response to BMP-2. Similarly,
binding of the SWI/SNF subunit Brg1 was also increased in
human primary osteoblasts after BMP-2 addition (Fig. 4B).
Altogether, these findings suggest that Osx and transcriptional
coactivators are recruited onto these promoter regions and
involved in the transcriptional program of induction of both
Fmod and Ibsp expression by BMP-2.
Osx Is Phosphorylated by p38—The fact that addition of
BMP-2 was able to further increase the responsiveness to Osx
of both the proximal Fmod and the Ibsp enhancer regions led us
to investigate the additional transcriptional effects of BMP-2 in
the expression of Fmod and Ibsp target genes. Interestingly,
SDS-PAGE analysis of cell extracts showed that both long and
short forms of Osx appeared as two species. To determine
whether the respective retarded bands were phosphorylated
forms, cell extracts from MC3T3-E1 cells after BMP-2 induc-
FIGURE 3. Fmod and Ibsp transcriptional activation by Osx and BMP-2.
A, cells were co-transfected with 2-kb pFmod-Luc reporter vector and either
mock or Osx construct overnight and treated with or without BMP-2 in
medium without serum for 24 h. B, cells were transfected with 2-kb pFmod-
Luc or pFmod300-Luc reporter vectors overnight and treated with BMP-2 in
medium without serum for 24 h. C, cells were co-transfected with pIbsp-Luc
reporter vector and either mock or Osx construct overnight and treated with
or without BMP-2 in medium without serum for 24 h. A, B, and C, luciferase
activity was measured and normalized against -galactosidase activity. Rela-
tive luciferase activities were expressed as mean  S.E. for triplicates from five
independent experiments (*, p  0.05; **, p  0.01; ***, p  0.001; one-way
ANOVA followed by Bonferroni’s multiple comparison test).
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tionwere treatedwith alkaline phosphatase. Phosphatase treat-
ment abrogated slow migrating forms, indicating that those
were due to phosphorylation events (Fig. 5A). Similar results
were obtained by exogenously overexpressing either long or
short forms of Osx, indicating that both forms were substrates
of cellular kinase(s) (Fig. 5A).
Activation of p38MAPK by BMP-2 has been shown to play
a relevant role in the osteogenic effects of this cytokine (21–
23). More specifically, the p38 pathway has been directly
implicated in the BMP-induced sequential recruitment of
the transcriptional coactivators p300 and the SWI/SNF
complex onto osteogenic genes (34, 36). We therefore ana-
lyzed whether Osx could be a target of the p38 pathway. In
agreement with previous reports (17), treatment of C2C12
FIGURE 4. Osx interaction with Sp1 regions in regulatory sites of Fmod and
Ibsp genes. A, upper panel, Sp1 regions analyzed by oligo pulldown. Biotinylated
(biot) oligonucleotide sequences used were as follows: F-1, 5-taggaatttggggcg-
ggaccctggt-biot; C-1, 5-ggaacagaaggggagggagc-biot; C-2, 5-cagggagtcccgcc-
tcctccaaac-biot; and C-2 mut, 5-cagggagtattgtttcctccaaac-biot. Lower panel, the
indicated double-stranded biotinylated oligonucleotides were incubated with
equal aliquots of extracts from C2C12 cells either transfected with an Osx con-
struct using mock as control or treated without (cto) or with BMP-2 in medium
without serum for 24 h. Precipitated complexes were analyzed by immunoblot-
ting using Osx antibody. B, upper panel, promoter regions analyzed by chromatin
immunoprecipitation. Lower panels, Saos-2 cells or human primary osteoblasts
(HOB) were treated with BMP-2 for 24 h in medium without serum. Cells were
fixed with formaldehyde, and chromatin immunoprecipitation analysis was per-
formed by incubating DNA-protein complexes using the indicated antibodies
and IgG as a control. Quantification of the results of two independent experi-
ments is shown below each panel as mean  S.E. Pol, polymerase.
FIGURE 5. Osx phosphorylation by p38. A, MC3T3-E1 cells were treated with
or without BMP-2 in medium without serum. C2C12 cells were transfected
with empty vector, short Osx, or long Osx constructs. After 24 h, cell extracts
were incubated with alkaline phosphatase (ALP) for 1 h. Osx forms were
detected by immunoblotting. B, cells were treated with or without BMP-2
in medium without serum for 24 h and pretreated with SB203580 (SB) for
30 min where indicated. Osx and tubulin were detected by immunoblot-
ting. C, C2C12 cells were co-transfected with constitutively active MKK6
(MKK6EE) and short or long Osx constructs. After 24 h, cells were treated with
SB203580 for 3 h. Osx, MKK6, and tubulin were detected by immunoblotting.
D, wild type (wt) and p38/ MEF cells were co-transfected with MKK6
construct and the short Osx construct. After 24 h, cells were treated with
SB203580 for 3 h. Osx, MKK6, and tubulin were detected by immunoblotting.
Arrows indicate phosphorylated forms.
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cells, MC3T3-E1 cells, or human primary osteoblasts with the
specific p38 inhibitor SB203580 inhibited the BMP-2-induced
expression of Osx (Fig. 5B). In addition to the decrease in total
expression, SB203580 reduced the phosphorylated Osx bands.
To further confirm the ability of p38 to phosphorylate Osx, we
used a constitutively active form of MKK6 (MKK6EE), which
phosphorylates and activates p38, and analyzed cell extracts
from C2C12 cells expressing either short or long forms of Osx.
The amount of the upper band corresponding to phosphory-
lated Osx was increased in the presence of MKK6EE compared
with extracts from cells expressing Osx alone (Fig. 5C). More-
over, treatment of cells with SB203580 significantly decreased
the amount of retarded bands. To further examine the require-
ment of distinct p38 isoforms forOsx phosphorylation, we ana-
lyzed MKK6EE-induced Osx phosphorylation in p38/
MEFs. MKK6EE induced phosphorylation of Osx in wild type
but not in p38/ MEFs (Fig. 5D). Taken together, these
results demonstrate that p38 MAPK is able to phosphorylate
Osx.
Osx Is Phosphorylated by p38 at Ser-73 and Ser-77—Se-
quence analysis of Osx revealed four distinct serines cor-
responding to consensus sites for MAPKs conserved in Osx
orthologs, and one of these was only present in the long form of
Osx. We generated site-specific mutants corresponding to the
two sites present in both long and short forms of Osx where Ser
was changed to Ala. Expression of MKK6EE induced the
appearance of retarded phosphorylated bands when co-trans-
fected with either the short or long forms of Osx (Fig. 6A).
However, both of the single point mutants S73A and S77A as
well as the double mutant S73A/S77A lost p38-dependent
phosphorylation and were detected exclusively as a single fast
migrating band irrespective of expression ofMKK6EE (Fig. 6A).
The fact that neither single mutant was phosphorylated by p38
may indicate that both of them are phosphorylated, or because
both sites are located very close to each other in a region of Osx
with a predicted coiled structure, Ser toAlamutation in one site
might also hinder phosphorylation at the other site.
We then examined whether Osx was a direct substrate of
p38 by in vitro phosphorylation assays using recombinant
proteins. Recombinant wild type Osx was phosphorylated in
vitro by activated recombinant p38, whereas the doublemutant
S73A/S77A showed impaired phosphorylation by p38 (Fig. 6B).
Analysis of the efficiency of this phosphorylation indicates that
addition of recombinant p38 induced almost a complete phos-
phorylation ofwild typeOsx, whereas the doublemutant S73A/
S77A only showed minor effects on either phosphorylation on
serines or in its electrophoretic mobility (Fig. 6B).
To examine the functional consequences of Osx phosphory-
lation, we first analyzed whether phosphorylation changed the
Osx protein turnover. Wild type and p38-defective MEFs
were transfected with Osx and MKK6EE and treated with the
protein synthesis inhibitor cycloheximide for different periods
of time. Quantification of the kinetics of Osx disappearance
displayed no significant differences between the phosphory-
lated and unphosphorylated forms of Osx. Similarly, the profile
of degradation ofOsxwas similar irrespective of the presence or
absence of MKK6EE or co-transfection of wild type Osx with
MKK6EE in p38/ MEFs (Fig. 6C).
p38 Phosphorylation Enhances Osx Transcriptional Activity
and Increases Its Interaction with Coactivators—To investigate
whether phosphorylation by p38 has a functional effect on Osx
transcriptional activity, C2C12 cells were transfected with
either Fmodor Ibsp promoter constructs, and cellswere treated
with BMP-2 in the presence or absence of the p38 inhibitor
SB203580. Increases in reporter activity induced by BMP-2
were significantly inhibited by addition of SB203580 in both
cases, suggesting a functional role for p38-induced Osx phos-
phorylation (Fig. 7A). We further analyzed the endogenous
expression of these target genes by RT-qPCR upon differentia-
tion of bone marrow mesenchymal stem cell cultures. Induc-
tion of Fmod and Ibsp gene expression by BMP-2 was reduced
in the presence of the p38 inhibitor SB203580 (Fig. 7B). In view
of these results, we assessed the relevance of Ser-73 and Ser-77
phosphorylation to the transcriptional activity ofOsx.Whereas
overexpression of Osx wild type led to a 2–3-fold induction of
the activity of Fmod and Ibsp reporter constructs, induction of
promoter activity by the S73A/S77A mutant construct was
significantly lower (Fig. 7C). Similarly, addition of BMP-2 fur-
ther increased the transcriptional activity of wild type Osx on
both reporters, whereas the mutant form showed impaired
responses to the cytokine addition (Fig. 7C). Likewise, we fur-
ther analyzed the endogenous expression of these target genes
FIGURE 6. Phosphorylation of Osx at Ser-73 and Ser-77 by p38. A, C2C12
cells were co-transfected with constitutively active MKK6 (MKK6EE) and the
different Osx constructs as indicated using an empty vector as control. B, 5 g
of GST-Osx wild type or the S73A/S77A mutant (mut) were incubated with
activated p38 MAPK (200 ng for each condition) in the presence of -[32P]ATP
and visualized by SDS-PAGE and autoradiography (left panel) or visualized by
immunoblotting against Osx or phosphoserine (pSer) (right panel). Addition
of MKK6-activated recombinant p38 is indicated by an asterisk (p38*). C, wild
type (wt) and p38/ MEF cells were co-transfected with MKK6EE and Osx
constructs as indicated. After 24 h, cells were treated with cycloheximide for
the indicated times. Osx was detected by immunoblotting. Quantification of
the results of three independent experiments is shown below each panel as
mean  S.E.
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by RT-qPCR. As expected, induction of Fmod and Ibsp endog-
enous genes by S73A/S77A Osx was reduced in comparison
with induction by wild typeOsx in both C2C12 andMC3T3-E1
cells (Fig. 7D).
To investigate the relevance of the phosphorylation ofOsx to
its binding and transcriptional activation of the Fmod and Ibsp
genes in vivo, we performed chromatin immunoprecipitation
assays in C2C12 cells transfected with wild type or double
mutantOsx. As shown in Fig. 8A, Osx bound to Fmodpromoter
and Ibsp enhancer. Increased Osx binding was sufficient to
recruit p300 and the RNA polymerase II to the Fmod promoter
and p300 to the Ibsp enhancer. More importantly, although
transfection efficiency and expression levels of either wild type
or mutant Osx were similar, binding of mutant Osx and its
ability to recruit RNA polymerase II, p300, or Brg1 to the Fmod
or Ibsp regulatory regions were lower, suggesting that phos-
phorylation of Osx enhances assembly of transcriptionally
active complexes in Osx target genes.
Because overexpression ofOsx is sufficient to induce recruit-
ment of p300 and Brg1 to the responsive promoters, we ana-
lyzed whether these factors might interact with each other
and studied the role of Osx phosphorylation in this interac-
tion. We analyzed the ability of Osx to interact with endog-
enous p300 and Brg1. Thus, we expressed FLAG-tagged wild
type and the S73A/S77A forms of Osx in C2C12 cells either
alone or together withMKK6EE. After immunoprecipitation of
Osx complexes, we foundp300 andBrg1 to be associated toOsx
by Western blot analysis (Fig. 8B). In addition, overexpression
of MKK6EE, which led to phosphorylated Osx, increased the
amounts of interacting p300 and Brg1, whereas addition of p38
inhibitor SB203580 decreased the binding of both transcrip-
tional coactivators. These interactions were mostly abrogated
when the Osx mutated form S73A/S77A was analyzed. More-
over, addition of BMP-2 to cells expressing FLAG-tagged wild
type Osx also increased interaction of Osx with p300 and Brg1.
These BMP-induced effects were partially abolished by addi-
tion of SB203580 (Fig. 8C). Taken together, our results strongly
suggest thatOsx binds to Sp1 sequences on target gene promot-
ers and that phosphorylation of Osx by p38 may enhance
recruitment of coactivators.
DISCUSSION
Osterix and Runx2 are widely considered to be master
osteogenic factors because neither Runx2- nor Osx-null
FIGURE 7. Induction of Osx transcriptional activity by p38 phosphoryla-
tion. A, C2C12 cells were transfected with either 2-kb pFmod-Luc or pIbsp-
Luc reporter vectors overnight, treated with or without BMP-2 in medium
without serum for 24 h, and pretreated with SB203580 (SB) for 30 min when
indicated. Luciferase activity was measured and normalized against -galac-
tosidase activity. Relative luciferase activities were expressed as mean  S.E.
for triplicates from four independent experiments (***, p  0.001; one-way
ANOVA followed by Bonferroni’s multiple comparison test). B, bone marrow
mesenchymal stem cells were cultured for 4 days and treated at a confluent
state at days 0 and 3 with BMP-2 (2 nM) and/or SB203580 during the last 24 h
in osteogenic differentiating medium. Fmod and Ibsp mRNAs were measured
by RT-qPCR, normalized to GAPDH, and expressed as relative expression 
S.E. of three independent experiments (***, p  0.001; two-way ANOVA fol-
lowed by Bonferroni’s multiple comparison test). C, C2C12 cells were
co-transfected with 2-kb pFmod-Luc or pIbsp-Luc vectors and mock, wild
type (wt), or double mutant (mut) Osx constructs and treated with or without
BMP-2 in medium without serum for 24 h. Luciferase activity was measured
and expressed as above (*, p  0.05; ***, p  0.001; two-way ANOVA followed
by Bonferroni’s multiple comparison test). D, cells were transfected with
mock, wild type (wt), or double mutant (mut) Osx constructs for 24 h. Fmod
and Ibsp mRNAs were measured by RT-qPCR, normalized to GAPDH, and
expressed as relative expression  S.E. of three independent experiments (**,
p  0.01; ***, p  0.001; two-way ANOVA followed by Bonferroni’s multiple
comparison test).
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mice formmature osteoblasts (11). Here, we show that expo-
sure of distinct mesenchymal and osteoblastic cells to BMP-2
induces the appearance of both the long and short Osx forms,
which also become phosphorylated by p38 MAPK. Our results
also emphasize the essential role of p38 and chromatin remod-
eling in the control of Osx expression and function. Osx, by
virtue of its binding to Sp1 sequences, activates transcription of
several target genes in osteoblasts and mesenchymal cell lines
such as Fmod and Ibsp. More importantly, we identified that
phosphorylation ofOsx by p38 at Ser-73/77 promotes assembly
of stable, transcriptionally active complexes containing Osx,
p300, and Brg1.
The essential role ofOsx in osteogenesis relies on its ability to
regulate the expression of a number of osteoblast markers such
as Osteopontin, Dkk1, and collagen type I. We identified Fmod
and Ibsp as novel osteoblastic genes regulated by Osx and char-
acterized Sp1 binding regions in their promoters that are able to
mediate BMP-2 and Osx activation. Our data constitute the
first evidence of the mechanisms of osteogenic regulation of
Fmod expression by Osx and BMP-2. In the case of Ibsp, func-
tional cooperativity was previously shown between the osteo-
genic factors Dlx5 and Runx2 in the proximal promoter of Ibsp
where Runx2 and Dlx5 bind to adjacent sites and physically
interact to drive promoter activation (37). There is some evi-
dence that Osx binding activity also plays an essential role in
mediating these effects on Ibsp expression. Previous studies
using 2.5- and 2.7-kb Ibsp promoters failed to show absolute
tissue-specific expression in transgenic mice (38) and required
at least a 9-kb promoter to show osteoblast-specific expression
(39). We identified an Ibsp enhancer region with an 80% se-
quence homology across human, mouse, and dog genes
(supplemental Fig. 1). This enhancer contains fully conserved
binding sites for Osx, Runx2, and homeodomain transcription
factors, suggesting that it could be critical for osteoblast-spe-
cific expression. Induction of Ibsp and Fmod by BMP-2 corre-
lates with that of Osx and requires at least 16–24 h to reach
maximal induction, whereas the induction of Runx2 and Dlx5
by BMP-2 requires much less time (17, 40). Similarly, the tem-
poral expression pattern in other models of differentiation of
osteoblast precursors indicates that the expression of Osx
always precedes that of Fmod, Ibsp, and other markers of ter-
minal differentiation such as osteocalcin or alkaline phospha-
tase. Finally, blocking the Osx function either in mice or cell
cultures leads to loss of expression of both Ibsp and Fmod (11,
15, 31, 41, 42). Altogether, our findings are consistent with the
idea that BMP-dependent induction of expression of late osteo-
genic markers depends on Osx and its cooperative action with
other osteogenic master genes.
Osx belong to the Sp1/Kruppel family of transcription fac-
tors that presents a marked preference for binding to GC-
rich motifs (43). However, because only a few mammalian
Osx-responsive promoters have been characterized, there is no
evidence for preferences to bind to specific motifs. Our results
suggest that Osx displays the ability to bind either the
GGGCGG or the GGGAGG sequences with, at least in vitro, a
higher DNA binding affinity to GGGCGG compared with
GGGAGG. Interestingly, our sequence analysis of the Osx-re-
sponsive Sp1 boxes in both Fmod and Ibsp promoters is con-
FIGURE 8. p300 and Brg1 recruitment induced by Osx phosphorylation.
A, C2C12 cells were transfected with mock, wild type (wt), or double mutant
(mut) Osx constructs for 24 h. Cells were fixed with formaldehyde, and chro-
matin immunoprecipitation analysis was performed by incubating DNA-pro-
tein complexes using the indicated antibodies. IgG was used as a control.
Quantification of the results of three independent experiments is shown
below each panel as mean  S.E. Expression of the constructs was analyzed by
immunoblotting. B, C2C12 cells were transfected with mock, FLAG-tagged
wild type (wt), or double mutant (mut) Osx constructs and constitutively
active MKK6 (MKK6EE) as indicated. After 24 h, cells were treated with
SB203580 (SB) for 3 h as indicated. Expression of the constructs and anti-
FLAG-co-immunoprecipitated proteins (IP-Flag) were analyzed by immuno-
blotting C, C2C12 cells were transfected with mock or FLAG-tagged wild type
Osx. After 24 h, cells were treated with BMP and/or SB203580 (SB) for 3 h as
indicated. Expression of the constructs and anti-FLAG-co-immunoprecipi-
tated proteins were analyzed by immunoblotting. Pol, polymerase.
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sistent with other Osx-responsive genes characterized like
Col1a1, Col11a2, and Dkk1. In all cases, the responsive motifs
in vitro and in vivo contain one of these two types of sequences
(14, 31, 41).
p38 MAPK is known to play an important role in several
steps of the osteoblast lineage progression and is necessary but
not sufficient for theBMP-induced acquisition of the osteoblast
phenotype (21, 44). Several evidences also indicate that p38
activity modulatesOsx expression induced by BMP in calvarial
as well as bone marrow-derived mesenchymal stem cells (17,
20, 24, 27). Similarly, other osteogenic stimuli such as mechan-
ical stress, drugs, or cytokines exert their osteogenic effects
through activation of p38 followed by an increase in Osx ex-
pression and function (17, 45–47). Our results provide amech-
anism bywhich BMP-2-activated p38 could enhance transcrip-
tional activity of Osx through direct phosphorylation on Ser-73
and Ser-77. First, activated p38 phosphorylates Osx in vitro and
in vivo. Second, phosphorylation of Osx is induced by the
expression of constitutively activeMKK6, whereas it is blocked
by the pharmacological inhibition of p38. Finally, p38-mediated
phosphorylation of Osx appears to increase its interaction with
the transcriptional coactivators p300 and Brg1. Indeed, the p38
inhibitor SB203580 inhibited BMP-2- and Osx-driven Fmod or
Ibsp promoter activation, and the mutant Osx S73A/S77A dis-
played reduced transcriptional activity and BMP-2 responsive-
ness. The existence of regulatory phosphorylations affecting
the activity of Sp1 is well known (32), and some reports indicate
that this also could be the case for Osx because it has been
shown to interact and becomedephosphorylated by calcineurin
(48). Regulatory effects of p38 phosphorylation were also
observed previously in Dlx5 transcriptional activity on the pro-
moter ofOsx itself (17). We therefore propose a positive osteo-
genic regulatory network where p38 activation regulates the
expression of Osx through Dlx5 phosphorylation and further
transcriptional activation of Osx through its phosphorylation
on Ser-73/77.
Ser-73 and Ser-77 are located in a solvent-exposed coiled
region of the proline- and serine-rich transactivation domain of
Osx. This region has been shown to interactwith cofactors such
as transcription factor IIB, a Jumonji family histone demethyl-
ase (NO66), and Brg1 through its zinc finger domain (15, 49).
Functionally equivalent regions of Sp1 have been shown to be
phosphorylated by distinct kinases, resulting in activity changes
based on their ability to recruit transcriptional cofactors (for a
review, see Ref. 32). Thus, it is likely that phosphorylation of
Osx in the transactivation domainmight modulate its ability to
recruit transcriptional cofactors.
Acetylation and/ormethylation at specific sites in histones in
chromatin is commonly associatedwith transcriptionally active
genes, and p300, histone deacetylases (HDACs), and the NO66
methylase have been shown to bind and regulate the acetylation
ormethylation of the core histones H3 andH4 in several osteo-
genic gene promoters. For instance, p300 is recruited to the
osteocalcin promoter in response to osteogenic signals (35, 50),
and JunB recruits p300 to activate dentin matrix protein 1
(Dmp1) (34), whereas HDAC4 inhibits Runx2 activity, and
HDAC4-null mice exhibit strong skeletal defects (51). BMPs
have been shown to switch recruitment from HDAC1 to p300
in osteocalcin, Osx, or Fgfr3 gene promoters and to promote
hypomethylation of CpG sites in Dlx5 and Osx promoter
regions (35–36, 52). Interestingly, BMP-2 has been shown to
increase binding of Osx to Ibsp or osteocalcin promoters with a
concomitant decrease of NO66 binding and activity (15). Sim-
ilarly, BMPs increase the expression and function of the ATP-
dependent chromatin-remodeling complex SWI/SNF, which
has been shown to be absolutely essential for osteogenesis,
especially the complexes containing Brg1 as a catalytic core
(53–55). Our study demonstrates that Osx is able to increase
recruitment of p300 and Brg1 to the promoters of its target
genes Fmod and Ibsp in vivo and that Osx directly associates to
these cofactors through protein-protein interactions that are
further enhanced by BMP signaling. Furthermore, phosphory-
lation of Osx at Ser-73/77 increases its ability to recruit p300
and SWI/SNF to Fmod or Ibsp promoter as has been shown for
p38-dependent recruitment of p300 by JunB on Dmp1 pro-
moter or by Sp1 to Fgfr3 promoter (34, 36). Recruitment of both
cofactors is likely to be cooperative because, in addition to its
histone acetyltransferase activity, the p300 protein may act as a
bridging factor to connect sequence-specific transcription fac-
tors to other cofactors and to the basal transcriptional machin-
ery, and acetylated chromatin is the preferred substrate for
SWI/SNF recruitment (56). In conclusion, Osx is able to up-
regulate Fmod and Ibsp expression levels through its ability to
recruit p300 andBrg1. Furthermore, phosphorylation ofOsx by
p38 is able to enhance the recruitment of these transcriptional
cofactors. Formation of this complex may initiate chromatin
remodeling responsible for the initiation and maintenance of
high transcription rates of their target genes.
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